Entellus Medical (ENTL) Tops Q1 EPS by 10c

Entellus Medical (NASDAQ: ENTL) reported Q1 EPS of ($0.37), $0.10 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $16.9 million versus the consensus estimate of $16.34 million.

“We are off to a strong start in 2016 with continued growth of our XprESS™ products in both the office and OR settings and are pleased with the initial uptake in pediatric procedures during the first quarter, augmenting procedure volumes in the OR,” said Robert White, President and Chief Executive Officer of Entellus Medical. “We expect a steady cadence of new product introductions throughout 2016 to drive continued growth in both office and OR settings throughout the year.

For earnings history and earnings-related data on Entellus Medical (ENTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c